You are here

Michael H. Wigler, PhD

Professor, Cancer Genetics
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York

Current Research

Goal: To understand the interaction between normal (host) cells and tumor cells that will inform new strategies to prevent or treat breast cancer.

Impact: Dr. Wigler and his team have developed two powerful methods that will help them in their work. One allows them to detect minute signals from cancer in a patient’s blood; the other identifies elements in host cells that associate with cancer at its various sites of growth.

What’s next: Using these methods, Dr. Wigler will study certain types of host cells that accompany cancer when it spreads to other locations in the body.

The environment that surrounds a tumor is composed of non-cancer cells and host factors—factors unique to each patient—that interact with tumor cells. These interactions influence the growth of the tumor as well as its response to therapy. Dr. Wigler is conducting studies to identify the types and functional states of cells in the “neighborhoods” around the tumor that could lead to new drug development for the prevention and treatment of breast cancer.

Full Research Summary

Research area: Finding and characterizing the cells of breast cancer patients that both fight and assist the cancer in its growth and spread.

Impact: Tumor cells interact with non-cancer cells and host factors, and this microenvironment influences tumor growth and its response to anti-cancer therapies. Dr. Wigler’s investigations of the host elements associated with tumor growth, response to therapy, and relapse could inform new generations of targeted therapies.

Current investigation: Dr. Wigler is focused on improving the technology and application of single-cell genomic methods, which allows researchers to study breast cancer at the single-cell level. He developed the first of these methods in 2011 with BCRF colleague James Hicks, PhD.

What he’s learned so far: He and his team developed two new powerful tools that will aid their research. The first allows for detecting minute signals from cancer in a patient’s blood; the second is a method for analysis of single-cell DNA and RNA at great depth, which will enable the identification of host cellular elements that associate with cancer at its various sites of growth.

What’s next: Dr. Wigler will use these tools to identify the types and functional states of cells that are common to multiple metastatic sites in breast cancer patients.


Cold Spring Harbor Laboratory scientist Michael Wigler, PhD, in collaboration with James Hicks, PhD, is analyzing the genomes of women with breast cancer in research aimed at eliminating "trial-and-error" approaches to therapy. This work is leading to diagnostic tests capable of distinguishing cancers likely to spread and should receive aggressive treatment from those that are benign and can be left untreated. In this effort, Drs. Wigler and Hicks are using powerful technologies that they developed to analyze genomic and epigenetic changes in thousands of breast cancers and have identified three distinct categories of breast cancer DNA profiles associated with different outcomes for patients. Their research has provided important information about which patients are most likely to benefit from treatment with specific drugs, such as taxol and Herceptin®. Drs. Wigler and Hicks have also developed a sensitive technology called single nucleus sequencing (SNS) that can identify genetic changes in very small samples, which can be used to follow genetic changes as tumors progress and to identify specific changes that can predict which tumors are likely to metastasize. The group is continuing to make technological improvements to make it affordable and feasible for SNS to be used as a monitoring tool for early detection of cancer cells in the blood, and to direct therapy based on the genetic makeup of those circulating cancer cells.

Grid Researcher Headshot - Wigler M

BCRF Investigator Since


Donor Recognition

The Play for P.I.N.K. Award / The Estée Lauder Companies' Breast Cancer Campaign Award